BioCentury on BioBusiness,
Worrying about clinical disclosure
Monday, May 13, 1996
Given that a significant number of biotech companies have rushed through the clinic with products not worth pursuing, or with poorly designed or executed trials, Wall Street has been forced over the years to become more sophisticated about clinical trials. In the process, the Street has demanded increasing amounts of ever-more-detailed information about clinical plans.
Listen to UBS analyst Tim Wilson: "I won't go near companies that won't tell me how they design their trials. The whole analytical process for 98 percent of the companies is factored around what they're planning to do in the clinic."
Biotech companies, because clinical trials represent material events, and because they depend on investors' money, have been forced to respond by disclosing information that their pharmaceutical cousins would never dream of discussing, including dosing, patient selection criteria and other factors that drive the end results.
But according to the companies, that information doesn't come without a price - a tradeoff between investment and competition.
"You can tell when you talk with investors that they don't want to hear there's a cost to their need for ever-more-detailed information," said David Robinson, president and CEO of Ligand Pharmaceuticals Inc. (LGND, San Diego, Calif.). "In an environment of managed care, where having an approved drug won't guarantee acceptance and being first in becomes more critical, the competitive window is clearly increasing in intensity.
"If you are giving away information that can materially assist your competitors, then it's very important to balance the interests of your shareholders in the disclosure of clinical strategies and clinical design versus assisting competitors to be more competitive with you downstream."
When it counts
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]